

# PRODUCT INFORMATION




## Cl-Amidine (hydrochloride)

Item No. 10599

Sold under license from the University of South Carolina under U.S. Patent No. 7,964,636.

**CAS Registry No.:** 1373232-26-8  
**Formal Name:** N-[(1S)-1-(aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide, monohydrochloride  
**MF:** C<sub>14</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub> • HCl  
**FW:** 347.2  
**Purity:** ≥95%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Cl-Amidine (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the Cl-amidine (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Cl-Amidine (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of Cl-amidine (hydrochloride) in these solvents is approximately 20, 50, and 14 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of Cl-amidine (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of Cl-amidine (hydrochloride) in PBS (pH 7.2) is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Cl-Amidine is an irreversible inhibitor of protein arginine deiminases (PADs; IC<sub>50</sub>s = 0.8, 6.2, and 5.9 μM for PAD1, PAD3, and PAD4, respectively).<sup>1-3</sup> It is cytotoxic to HL-60, MCF-7, and HT-29 cancer cells (IC<sub>50</sub>s = 0.25, 0.05, and 1 μM, respectively).<sup>4</sup> Cl-amidine (50 mg/kg) reduces *ex vivo* extracellular neutrophil extracellular trap (NET) formation and increases survival in a mouse model of sepsis induced by cecal ligation and puncture (CLP).<sup>5</sup> It also decreases the citrulline content in serum and joints and reduces the development of IgG autoantibodies in a mouse model of collagen-induced arthritis in a dose-dependent manner.<sup>6</sup>

### References

1. Luo, Y., Arita, K., Bhatia, M., *et al.* *Biochemistry* **45**(39), 11727-11736 (2006).
2. Knuckley, B., Causey, C.P., Jones, J.E., *et al.* *Biochem.* **49**(23), 1-28 (2010).
3. Muth, A., Subramanian, V., Beaumont, E., *et al.* *J. Med. Chem.* **60**(7), 3198-3211 (2017).
4. Slack, J.L., Causey, C.P., and Thompson, P.R. *Cell. Mol. Life Sci.* **68**(4), 709-720 (2011).
5. Biron, B.M., Chung, C.-S., O'Brien, X.M., *et al.* *J. Innate Immun.* **9**(1), 22-32 (2017).
6. Willis, V.C., Gizinski, A.M., Banda, N.K., *et al.* *J. Immunol.* **186**(7), 4396-4404 (2011).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/29/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM